Clinical Trials

28 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

21 enrolled

Prostatic Neoplasms

NCT04742075 2026-02-27

DOVACC

188 enrolled

Phase EARLY_PHASE1 Active not recruiting

Ovarian Neoplasms

NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

15 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04417062 2026-02-25

Olaparib With Ceralasertib in Recurrent Osteosarcoma

63 enrolled

Sarcoma

Osteosarcoma

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

10 enrolled

Breast Neoplasms

NCT04065269 2026-02-20

ATARI

174 enrolled

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

96 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

96 enrolled

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT03085147 2026-02-12

A Dye for the Detection of Cancer of the Tongue and Mouth

23 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05366166 2026-01-28

Pembrolizumab Plus Olaparib in LA-HNSCC

45 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05203445 2026-01-12

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

23 enrolled

Breast Neoplasms

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

BreastClassical hematology

114 enrolled

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT03212742 2025-12-04

OLA-TMZ-RTE-01

91 enrolled

CNS

Glioma

NCT04209686 2025-12-03

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

36 enrolled

Stomach Neoplasms

NCT04643379 2025-10-22

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03012321 2025-10-21

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

70 enrolled

Prostatic Neoplasms

NCT03162627 2025-10-14

Selumetinib and Olaparib in Solid Tumors

90 enrolled

Breast Neoplasms

NCT05156268 2025-08-17

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

26 enrolled

GynecologicSarcoma

Endometrial Carcinosarcoma

NCT05379972 2025-07-16

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

9 enrolled

Stomach Neoplasms

NCT03047135 2025-06-17

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

51 enrolled 8 charts

Prostate

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

50 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03874884 2025-05-14

LuPARP

70 enrolled

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03594396 2025-04-17

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

54 enrolled

Breast Neoplasms

NCT03787680 2025-03-28

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

49 enrolled 11 charts

Prostatic Neoplasms

NCT04053322 2025-03-12

DOLAF

172 enrolled

Phase EARLY_PHASE1 Active not recruiting

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer

NCT04614909 2025-02-28

Study of Pamiparib in Newly Diagnosed and rGBM

45 enrolled

CNS

Glioblastoma

NCT04487587 2025-02-26

COMICE

79 enrolled

Uterine Cervical Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT05358639 2024-11-18

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

36 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03967938 2024-08-19

1-2018 BSMO

540 enrolled

Advanced Cancers Harbouring Mutations in HRG

NCT02308072 2024-05-08

ORCA-2

70 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05033756 2024-05-07

COMPRENDO

11 enrolled

Breast Neoplasms

NCT03579784 2024-04-19

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

40 enrolled

Advanced Gastric Cancer

NCT04298021 2024-04-19

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

74 enrolled

Bile Duct Neoplasms

NCT04169841 2024-02-13

GUIDE2REPAIR